On April 1, 2026, the Instituto Nacional de Câncer (INCA), Brazil's premier cancer research and control institute, unveiled a landmark pilot study aimed at establishing a national lung cancer screening program within the Sistema Único de Saúde (SUS), the country's universal public health system. This initiative marks a pivotal step toward early detection of lung cancer, a disease that claims tens of thousands of lives annually in Brazil. The announcement, held at the Auditório Ivo Pitanguy in Rio de Janeiro, featured prominent participation from Dra. Clarissa Baldotto, President of the Sociedade Brasileira de Oncologia Clínica (SBOC), alongside INCA leadership and representatives from municipal health authorities.

The event underscored a collaborative effort involving the Ministry of Health, Fundação Oswaldo Cruz (Fiocruz), and the Rio de Janeiro Municipal Health Secretariat. Dr. Roberto de Almeida Gil, INCA's director-general, highlighted the urgency, noting that lung cancer is the leading cause of cancer mortality in Brazil. Dra. Baldotto emphasized the need for integrated science, public policy, and clinical practice to overhaul the landscape of lung cancer care.

🔬 The Growing Burden of Lung Cancer in Brazil

Lung cancer remains a formidable public health challenge in Brazil. According to INCA projections for the 2026-2028 triennium, the country anticipates approximately 781,000 new cancer cases annually, with lung cancer accounting for about 6.8%—roughly 35,380 incidents per year when excluding non-melanoma skin cancers. In 2024 alone, it caused 32,465 deaths, predominantly among men but increasingly affecting women and younger demographics due to aging populations, sedentary lifestyles, and persistent tobacco use.

Alarmingly, 84-90% of cases are diagnosed at advanced stages, where five-year survival rates plummet to around 5%. Tobacco smoking drives 85% of incidences, yet Brazil lacks a structured national screening protocol comparable to mammography for breast cancer or Pap smears for cervical cancer. This gap perpetuates late diagnoses, straining SUS resources with high-cost treatments for metastatic disease.

Regional disparities exacerbate the issue: higher infection-related cancers in the North and Northeast, but lung cancer's toll is nationwide. Universities like the Universidade de São Paulo (USP) and Universidade Federal de São Paulo (UNIFESP) have contributed pivotal data through epidemiological studies, underscoring the academic backbone supporting policy shifts.

Demystifying Low-Dose Computed Tomography (LDCT) Screening

Low-dose computed tomography (LDCT), or tomografia computadorizada de baixa dose (TCBD) in Portuguese, is the gold-standard screening tool. Unlike standard CT scans, LDCT uses significantly reduced radiation—about 1/10th the dose—making it safer for annual or biennial use in high-risk groups. It excels at detecting small pulmonary nodules, often cancerous, before symptoms manifest.

The process involves: (1) Eligibility assessment via smoking history; (2) Baseline LDCT scan; (3) Follow-up imaging for indeterminate nodules; (4) Biopsy or surveillance for suspicious findings; (5) Integration with smoking cessation programs. Step-by-step protocols minimize false positives (common challenge, ~25% in trials) through nodule size, growth rate, and AI-assisted analysis increasingly adopted in Brazilian research institutions.

Pioneering trials like the U.S. National Lung Screening Trial (NLST) showed 20% mortality reduction; Europe's NELSON trial confirmed 24-39% drops. Brazilian academics have modeled similar benefits, validating LDCT's cost-effectiveness in SUS contexts.

Inside the INCA Pilot Study: Design and Scope

This two-year prospective study, led by INCA epidemiologist Dr. Arn Migowski do Santos (also SBOC Prevention Committee member), recruits from Rio's Smoking Cessation Program. Initial cohort: minimum 397 high-risk individuals, expandable based on interim results.

• Eligibility: Age 50-80; ≥20 pack-years (e.g., 1 pack/day for 20 years); current smokers or quit <15 years; no prior lung cancer, unexplained weight loss, hemoptysis, or chest CT in past year.
• Protocol: Annual LDCT; multidisciplinary review for positives; linkage to SUS care pathways.
• Endpoints: Detection rates, stage shift, cost per life-year saved, implementation barriers.

Funded by AstraZeneca, it builds on prior cost-effectiveness analyses confirming LDCT viability in SUS, where incremental cost-effectiveness ratio falls below R$20,000 per quality-adjusted life year—far superior to many oncology therapies.

Photo by Gustavo Leighton on Unsplash

Dra. Clarissa Baldotto's Vision: Bridging Academia and Public Health

Dra. Baldotto, a Universidade Federal Fluminense (UFF) alumna with advanced training at INCA, embodies the academic-clinician nexus. As SBOC President since early 2026, she advocated at the launch: "Combating tobacco is paramount, but SUS must deliver early diagnosis and treatment. Screening isn't just a scan—it's a care continuum." Her leadership unites societies like SBOC, Sociedade Brasileira de Cirurgia Torácica (SBCT), and Colégio Brasileiro de Radiologia (CBR) for evidence-based guidelines.

Baldotto's career highlights university-hospital synergies: from UFF graduation to INCA master's, her work informs thoracic oncology curricula nationwide, training future specialists amid rising caseloads.

Academic Research Powering the Initiative

Brazilian universities underpin this effort. Recent ASCO-published modeling from national researchers affirms LDCT's affordability in SUS high-risk cohorts. Institutions like USP and UNIFESP contribute via cohort studies and AI nodule detection tools, vital for scaling screening. Fiocruz-INCA collaborations foster PhD programs in oncology epidemiology, producing experts like Migowski.

Universities train radiologists in LDCT protocols—critical as Brazil boasts ~5,000 CT scanners, many underutilized. Programs at UFRJ and Unicamp integrate screening simulations, preparing graduates for SUS demands. This study could spur federal grants, boosting research jobs in public health faculties.Explore the cost-effectiveness analysis here.

Overcoming Implementation Hurdles in SUS

Challenges abound: false positives risk unnecessary biopsies; tuberculosis mimics nodules; rural access lags. Solutions include risk calculators tailored to Brazilian demographics (e.g., incorporating Chagas disease) and telemedicine from university hubs.

Prior pilots like Lungevity-BR validated feasibility; this scales nationally.SBOC announcement details.

Global Lessons and Brazilian Innovation

U.S. NLST (20% mortality drop) and Italy's ITALUNG inform design, but Brazil adapts for diversity—e.g., higher TB prevalence. Unicamp's AI prototypes reduce radiologist workload by 40%, positioning Brazilian academia as leaders.

Stakeholders: AstraZeneca funds; societies endorse; universities provide evidence base.

Photo by Gustavo Leighton on Unsplash

Implications for Oncology Careers and Higher Education

This heralds expanded research roles: fellowships in screening trials, uni-led cohorts. Brazil's 200+ med schools can integrate LDCT into curricula, addressing oncologist shortages (1 per 100k vs. WHO 4). Job prospects soar in SUS-university hybrids, from postdocs to faculty positions in thoracic oncology.

Prospective students: Pursue residencies at INCA-affiliated unis like UFF, USP for frontline impact.

Outlook: Toward a National Program

Success could screen 1M+ annually, averting 7,000 deaths/year. Universities gear up for trials, training, tech transfer—solidifying Brazil's oncology research prowess. Dra. Baldotto's call: "SBOC stands ready." Watch for 2028 rollout.

For researchers, this opens grants via CNPq/FAPs; explore opportunities in public health oncology.INCA resources.